Kyle Alexander Bolo

Kyle Bolo practices at Keck Medicine of USC - USC Roski Eye Institute - Ophthalmology - HOPD in Los Angeles, California.

Kyle Bolo's NPI, 1154984417, was assigned on April 22, 2019. Kyle Bolo graduated from Vagelos College of Physicians and Surgeons in 2019. Kyle Bolo holds California license 181420.

Kyle Bolo's primary practice is Keck Medicine of USC - USC Roski Eye Institute - Ophthalmology - HOPD, at 1450 San Pablo St, Los Angeles, CA 90033.

Kyle Bolo's primary practice is Keck Medicine of USC - USC Roski Eye Institute - Ophthalmology - HOPD in Los Angeles, California. Kyle Bolo is also affiliated with Keck Hospital of USC. The medical group on file is UC San Diego Health. Dmand AI also links Kyle Bolo to 2 more group practices and clinics and 1 medical group, each named with a free account. Kyle Bolo's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Kyle Bolo practices, 4 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Kyle Bolo's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Kyle Bolo is board certified in ophthalmology by the American Board of Ophthalmology. Kyle Bolo is licensed in California.

Dmand AI lists glaucoma among the conditions Kyle Bolo treats.

CMS data shows 161 Medicare services from Kyle Bolo across 4 procedure codes in 2024, for 109 Medicare patients. Medicare paid $10,710 for them. Every service was in an office.

CMS counts 109 Medicare patients who saw Kyle Bolo in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 33% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Kyle Bolo's median patient age at 65, with 59% women.

In 2024, Kyle Bolo wrote 1,784 Medicare Part D claims for 554 patients. 59% of them were for generic drugs. CMS names the drug for 1,717 of them, across 18 drugs with 11 or more claims each, at $155,249 in total drug cost. In 2023, CMS named 710 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Kyle Bolo for performance year 2024, reported as part of a group. Kyle Bolo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 73 procedures of cataract surgery by Kyle Bolo, more than 70% of the clinicians it reports for that procedure.

Dmand AI links 2 papers to Kyle Bolo in 2024. Kyle Bolo's most frequent co-authors are Justin John Arnett, MD, Malvika Arya, MD and Sally Liu Baxter, MD.

CMS Open Payments shows 57 general payments to Kyle Bolo from 10 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 95% of the total. Abbvie Inc. paid the most, $1,997.

Kyle Bolo graduated from Vagelos College of Physicians and Surgeons in 2019.

Kyle Bolo is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.